감염증 POC(Point of Care) 진단 시장 : 규모, 점유율, 성장, 업계 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of infectious disease point-of-care (POC) diagnostics Market

The global infectious disease point-of-care (POC) diagnostics market is undergoing a notable transition due to shifting healthcare priorities and evolving diagnostic technologies. The market was valued at USD 14.37 billion in 2025 and is projected to decline to USD 13.97 billion in 2026, further reaching USD 11.13 billion by 2034, reflecting a CAGR of -2.80% during the forecast period. Despite the decline, North America dominated the market with a 36.30% share in 2025, driven by strong healthcare infrastructure and continuous product innovations.

Point-of-care diagnostics enable rapid disease detection near the patient, eliminating the need for centralized laboratory testing. These tests provide results within 15-30 minutes, improving treatment decisions and patient outcomes. Technological advancements such as multiplex point-of-care testing (MPOCT), microfluidics, and nanotechnology have enhanced accuracy, speed, and usability, making these solutions vital in modern healthcare systems.

Market Dynamics

Growth Drivers

The increasing global prevalence of infectious diseases such as HIV, hepatitis, influenza, and tuberculosis remains a major driver for POC diagnostics. According to global health data, millions of people are affected annually, creating sustained demand for rapid and accessible diagnostic solutions.

Another important driver is the shift toward decentralized healthcare systems. Point-of-care testing allows diagnosis in clinics, homes, and remote settings, reducing dependency on centralized laboratories. This trend gained momentum during the COVID-19 pandemic and continues to influence healthcare delivery models.

Additionally, technological advancements in diagnostic platforms, including molecular diagnostics and nanotechnology-based testing, are improving sensitivity and reducing turnaround time. These innovations are expanding the application scope of POC diagnostics across multiple diseases.

Market Restraints

Despite these drivers, the market is experiencing a decline due to reduced demand post-COVID-19 pandemic, as emergency testing requirements have subsided. Furthermore, accuracy concerns and lack of skilled professionals in developing regions limit adoption. Errors caused by improper handling and insufficient training continue to challenge market growth.

Market Trends

A key trend shaping the market is the integration of nanotechnology in diagnostic devices. Nanoparticle-based tests offer high sensitivity and rapid detection, often requiring minimal sample volumes. These innovations are attracting significant research investments and improving diagnostic capabilities.

Another trend is the development of multiplex diagnostic platforms, which allow simultaneous detection of multiple pathogens in a single test. This enhances efficiency and reduces testing time, especially in critical care settings.

The market is also witnessing increased adoption of home-based and self-testing kits, reflecting a shift toward patient-centric healthcare and convenience-driven diagnostics.

Segmentation Analysis

By technique, the market includes lateral flow immunoassay, molecular diagnostics, agglutination tests, and flow-through assays. The lateral flow immunoassay segment dominates due to its simplicity, rapid results, and widespread availability. It is expected to hold a 31.2% share in 2026.

By disease, the market covers HIV, influenza, tuberculosis, hepatitis, MRSA, and others. Among these, clostridium difficile infections (CDI) hold a significant share due to high prevalence and increased testing demand in hospitals.

By end-user, the market is segmented into hospital bedside, physician offices, urgent care clinics, home testing, and nursing homes. The hospital bedside segment leads, driven by the growing number of hospitalized patients and the need for immediate diagnostic results. Meanwhile, home testing and urgent care clinics are gaining traction due to convenience and accessibility.

Regional Insights

North America leads the market with a value of USD 5.22 billion in 2025 and USD 5.07 billion in 2026, supported by advanced healthcare systems, strong regulatory approvals, and strategic collaborations among key players.

Europe holds the second-largest share, driven by mergers, acquisitions, and product portfolio expansion by major companies. Asia Pacific is expected to witness the highest growth potential, supported by increasing healthcare investments, rising disease burden, and expanding access to diagnostic technologies in countries such as China and India.

Latin America and the Middle East & Africa show slower growth due to limited awareness and lower healthcare spending, though gradual improvements in infrastructure are expected to support future demand.

Competitive Landscape

The market is semi-consolidated, with leading players such as F. Hoffmann-La Roche Ltd, Abbott Laboratories, Cepheid Inc., Thermo Fisher Scientific, and BD. These companies focus on product innovation, strategic partnerships, and acquisitions to strengthen their market presence.

Recent developments include the launch of rapid diagnostic kits, multiplex assays, and portable testing devices, highlighting continuous innovation in the sector.

Conclusion

The infectious disease point-of-care diagnostics market is projected to decline from USD 14.37 billion in 2025 to USD 11.13 billion by 2034, primarily due to reduced post-pandemic demand and operational challenges. However, ongoing advancements in diagnostic technologies, increasing disease prevalence, and the shift toward decentralized healthcare will continue to support long-term relevance and innovation in the market.

Segmentation By Technique

• Lateral Flow Immunoassay (LFIA)
• Agglutination Test
• Flow-through test/Immunoconcentration Assay
• Molecular Diagnostics
• Others

By Disease

• HIV
• Hepatitis B Virus
• Pneumonia/Streptococcus Associated Infections
• Respiratory Syncytial Virus (RSV)
• Influenza
• Clostridium Difficile Infections (CDI)
• Hepatitis C Virus
• Methicillin-Resistant Staphylococcus Aureus (MRSA)
• Tuberculosis (TB)
• COVID-19
• Others

By End-User

• Hospital Bedside
• Physician's Office Lab
• Urgent Care & Retail Clinics
• Home & Self-testing
• Nursing Home
• Others

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and Rest of Latin America)
• Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Infectious Diseases, By Key Countries, 2025
• 4.2. New Product Launches
• 4.3. Key Industrial Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.4. Technological Advancements in Infectious Disease Point of Care (POC) Diagnostics
• 4.5. Impact of COVID-19 on Infectious Disease Point of Care (POC) Diagnostics Market
• 4.6. Overview of Initiatives for Infectious Disease Point of Care (POC) Diagnostics in Emerging Countries
• 4.7. Pricing Analysis of Various Infectious Disease Point of Care (POC) Diagnostics, By Key Companies
• 4.8. Analysis of Product Features of Key Infectious Disease Point of Care (POC) Diagnostics, By Key Companies

5. Global Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Technique
  • 5.1.1. Lateral Flow Immunoassay (LFIA)
  • 5.1.2. Agglutination Tests
  • 5.1.3. Flow-through Tests / Immunoconcentration Assays
  • 5.1.4. Molecular Diagnostics
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Disease
  • 5.2.1. Human Immunodeficiency Virus (HIV)
  • 5.2.2. Hepatitis B Virus (HBV)
  • 5.2.3. Pneumonia / Streptococcus Associated Infections
  • 5.2.4. Respiratory Syncytial Virus (RSV)
  • 5.2.5. Influenza
  • 5.2.6. Clostridium difficile infection (CDI)
  • 5.2.7. Hepatitis C Virus (HCV)
  • 5.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • 5.2.9. Tuberculosis (TB)
  • 5.2.10. COVID-19
  • 5.2.11. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospital Bedside
  • 5.3.2. Physician's Office Lab
  • 5.3.3. Urgent Care & Retail Clinics
  • 5.3.4. Home & Self-Testing
  • 5.3.5. Nursing Homes
  • 5.3.6. Others
• 5.4. Market Analysis, Insights and Forecast - By Geography
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Technique
  • 6.1.1. Lateral Flow Immunoassay (LFIA)
  • 6.1.2. Agglutination Tests
  • 6.1.3. Flow-through Tests / Immunoconcentration Assays
  • 6.1.4. Molecular Diagnostics
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Disease
  • 6.2.1. Human Immunodeficiency Virus (HIV)
  • 6.2.2. Hepatitis B Virus (HBV)
  • 6.2.3. Pneumonia / Streptococcus Associated Infections
  • 6.2.4. Respiratory Syncytial Virus (RSV)
  • 6.2.5. Influenza
  • 6.2.6. Clostridium difficile infection (CDI)
  • 6.2.7. Hepatitis C Virus (HCV)
  • 6.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • 6.2.9. Tuberculosis (TB)
  • 6.2.10. COVID-19
  • 6.2.11. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospital Bedside
  • 6.3.2. Physician's Office Lab
  • 6.3.3. Urgent Care & Retail Clinics
  • 6.3.4. Home & Self-Testing
  • 6.3.5. Nursing Homes
  • 6.3.6. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Technique
  • 7.1.1. Lateral Flow Immunoassay (LFIA)
  • 7.1.2. Agglutination Tests
  • 7.1.3. Flow-through Tests / Immunoconcentration Assays
  • 7.1.4. Molecular Diagnostics
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Disease
  • 7.2.1. Human Immunodeficiency Virus (HIV)
  • 7.2.2. Hepatitis B Virus (HBV)
  • 7.2.3. Pneumonia / Streptococcus Associated Infections
  • 7.2.4. Respiratory Syncytial Virus (RSV)
  • 7.2.5. Influenza
  • 7.2.6. Clostridium difficile infection (CDI)
  • 7.2.7. Hepatitis C Virus (HCV)
  • 7.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • 7.2.9. Tuberculosis (TB)
  • 7.2.10. COVID-19
  • 7.2.11. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospital Bedside
  • 7.3.2. Physician's Office Lab
  • 7.3.3. Urgent Care & Retail Clinics
  • 7.3.4. Home & Self-Testing
  • 7.3.5. Nursing Homes
  • 7.3.6. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Technique
  • 8.1.1. Lateral Flow Immunoassay (LFIA)
  • 8.1.2. Agglutination Tests
  • 8.1.3. Flow-through Tests / Immunoconcentration Assays
  • 8.1.4. Molecular Diagnostics
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Disease
  • 8.2.1. Human Immunodeficiency Virus (HIV)
  • 8.2.2. Hepatitis B Virus (HBV)
  • 8.2.3. Pneumonia / Streptococcus Associated Infections
  • 8.2.4. Respiratory Syncytial Virus (RSV)
  • 8.2.5. Influenza
  • 8.2.6. Clostridium difficile infection (CDI)
  • 8.2.7. Hepatitis C Virus (HCV)
  • 8.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • 8.2.9. Tuberculosis (TB)
  • 8.2.10. COVID-19
  • 8.2.11. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospital Bedside
  • 8.3.2. Physician's Office Lab
  • 8.3.3. Urgent Care & Retail Clinics
  • 8.3.4. Home & Self-Testing
  • 8.3.5. Nursing Homes
  • 8.3.6. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Technique
  • 9.1.1. Lateral Flow Immunoassay (LFIA)
  • 9.1.2. Agglutination Tests
  • 9.1.3. Flow-through Tests / Immunoconcentration Assays
  • 9.1.4. Molecular Diagnostics
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Disease
  • 9.2.1. Human Immunodeficiency Virus (HIV)
  • 9.2.2. Hepatitis B Virus (HBV)
  • 9.2.3. Pneumonia / Streptococcus Associated Infections
  • 9.2.4. Respiratory Syncytial Virus (RSV)
  • 9.2.5. Influenza
  • 9.2.6. Clostridium difficile infection (CDI)
  • 9.2.7. Hepatitis C Virus (HCV)
  • 9.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • 9.2.9. Tuberculosis (TB)
  • 9.2.10. COVID-19
  • 9.2.11. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospital Bedside
  • 9.3.2. Physician's Office Lab
  • 9.3.3. Urgent Care & Retail Clinics
  • 9.3.4. Home & Self-Testing
  • 9.3.5. Nursing Homes
  • 9.3.6. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Technique
  • 10.1.1. Lateral Flow Immunoassay (LFIA)
  • 10.1.2. Agglutination Tests
  • 10.1.3. Flow-through Tests / Immunoconcentration Assays
  • 10.1.4. Molecular Diagnostics
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Disease
  • 10.2.1. Human Immunodeficiency Virus (HIV)
  • 10.2.2. Hepatitis B Virus (HBV)
  • 10.2.3. Pneumonia / Streptococcus Associated Infections
  • 10.2.4. Respiratory Syncytial Virus (RSV)
  • 10.2.5. Influenza
  • 10.2.6. Clostridium difficile infection (CDI)
  • 10.2.7. Hepatitis C Virus (HCV)
  • 10.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • 10.2.9. Tuberculosis (TB)
  • 10.2.10. COVID-19
  • 10.2.11. Others
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospital Bedside
  • 10.3.2. Physician's Office Lab
  • 10.3.3. Urgent Care & Retail Clinics
  • 10.3.4. Home & Self-Testing
  • 10.3.5. Nursing Homes
  • 10.3.6. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. F. Hoffmann-La Roche Ltd
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Thermo Fisher Scientific Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Quest Diagnostics Incorporated
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. BD
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. bioMerieux SA
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Cardinal Health, Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Cepheid
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Mesa Biotech
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Trinity Biotech
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Quidel Corporation
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. Bio-Rad Laboratories, Inc.
    • 11.2.11.1. Overview
    • 11.2.11.2. Products
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)
  • 11.2.12. Abbott
    • 11.2.12.1. Overview
    • 11.2.12.2. Products
    • 11.2.12.3. SWOT Analysis
    • 11.2.12.4. Recent Developments
    • 11.2.12.5. Strategies
    • 11.2.12.6. Financials (Based on Availability)
  • 11.2.13. Other Prominent Players